Pixantrone maleate for non-Hodgkin's lymphoma

Drugs of Today

Volumn 45, Issue 11, 2009, Pages 797-805

  Mukherji, Deborah ^a   Pettengell, Ruth ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GEMCITABINE; HYDROXYL GROUP; IFOSFAMIDE; METHYLPREDNISOLONE; MITOXANTRONE; NAVELBINE; OXALIPLATIN; PIXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ALOPECIA; ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; BREAST CANCER; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CYLINDROMA; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; FEBRILE NEUTROPENIA; HEART FAILURE; HEART INJURY; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERGLYCEMIA; LARGE CELL LYMPHOMA; LETHARGY; LEUKOPENIA; LUNG SMALL CELL CANCER; LYMPHOCYTOPENIA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; REVIEW; SIDE EFFECT; SKIN DISCOLORATION; THROMBOCYTOPENIA; URINE COLOR;

EID: 77749240479     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2009.45.11.1438459     Document Type: Review

References (31)

1. Steinherz, L.J., Steinherz, P.G., Tan, C.T., Heller, G., Murphy, M.L. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991, 266(12): 1672-7.
2. Jensen, B.V., Skovsguaard, T., Nielsen, S.L. Functional monitoring of anthracycline cardiotoxicity: A prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 2002, 13(5): 699-709.
3. Von Hoff, D.D., Layard, M.W., Basa, P., Davis, H.L. Jr., Von Hoff, L.L., Rozencweig, M., Muggia, F.M. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979, 91(5): 710-7.
4. van Dalen, E.C., van der Pal, H.J., Bakker, P.J., Caron, H.N., Kremer, L.C. Cumulative incidence and risk factors of mitoxontrone-induced cardiotoxicity in children: A systematic review. Eur J Cancer 2004, 40(5): 643-52.
5. Denny, W.A., Wakelin, L.P.G. Kinetics and binding of mitoxantrone, ametantrone and analogues to DNA: Relationship with binding mode and antitumour activity. Anti-Cancer Drug Design 1990, 5(3): 189-200.
6. Beggiolin, G., Crippa, L., Menta, E. et al. BBR 2778, an anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity. Tumori 2001, 87(6): 407-16.
7. Krapcho, A.P., Maresch, M.J., Hacker, M.P. et al. Anthracene-9,10- diones and aza bioisoteres an antitumour agents. Curr Med Chem 1995, 2: 803-24.
8. De Isabella, P., Palumbo, M., Sissi, C. et al. Topoisomerase II DNA cleavage Stimulation, DNA binding activity, cytotoxicity and physico-chemical properties of 2-aza and 2-aza-oxide-anthracenedione derivatives. Mol Pharmacol 1995, 48(1): 30-8.
9. Hazlehurst, L.A., Krapcho, A.P., Hacker, M.P. Comparison of aza-anthracenedione-induced DNA damage and cytotoxicity in experimental tumor cells. Biochem Pharmacol 1995, 50(7): 1087-94.
10. Zwelling, L.A., Mayes, J., Cltschuler, E., Satitpunwaycha, P., Tritton, T.R., Hacker, M.P. Activity of two novel antrhracene-9,10-diones against human leukaemia cells containing inercalator-sensitive or -resistant forms of topoisomerase II. Biochem Pharmacol 1993, 46(2): 265-71.
11. Evison, B.J., Mansour, O.C., Menta, E., Phillips, D.R., Cutts, S.M. Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agent. Nucleic Acids Res 2007, 35(11): 3581-9.
12. Evison, B.J., Chiu, F., Pezzoni, G., Phillips, D.R., Cutts, S.M. Formaldehyde-activated pixantrone is a monofunctional DNA alkylator that binds selectively to CpG and CpA doublets. Mol Pharmacol 2008, 74(1): 184-94.
13. Evison, B.J., Bilardi, R.A., Chiu, F., Pezzoni, G., Phillips, D.R., Cutts, S.M. CpG methylation potentiates pixantrone and doxorubicin-induced DNA damage and is a marker of drug sensitivity. Nucleic Acids Res 2009, 37(19): 6355-70.
14. Cavalletti, E., Crippa, L., Mainardi, P., Oggioni, N., Cavagnoli, R., Bellini, O., Sala, F. Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: Comparative studies against doxorubicin and mitoxantrone. Invest New Drugs 2007, 25(3): 187-95.
15. Dawson, L.K., Jodrell, D.I., Bowman, A. et al. A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenidone analogue, administered intravenously, 3 weekly. Eur J Cancer 2000, 36(18): 2353-9.
16. Faivre, S., Raymond, E., Boige, V. et al. A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies. Clinical Cancer Res 2001, 7(1): 43-50.
17. Borchmann, P., Schnell, R., Knippertz, R. et al. Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma. Ann Oncol 2001, 12(5): 661-7.
18. Josting, A., Reiser, M., Ruffer, U., Salzberger, B., Diehl, V., Engert, A. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: Is there a chance for cure? J Clin Oncol 2000, 18(2): 322-9.
19. Borchmann, P., Morschhauser, F., Parry, A. et al. Phase II study of the new aza-anthracenidone, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas. Haematologica 2003, 88(8): 888-94.
20. Pettengell, R., Narayanan, G., Mendoza, F.H., Digumarti, R., Gomez, H., Cernohous, P., Gorbatchevskey, I. Randomized phase III trial of pixantrone compared with other chemotherapeutic agents for third-line single-agent treatment of relapsed aggressive non-Hodgkin's lymphoma. J Clin Oncol 2009, 27: 15s (Abst 8523).
21. http://investors.celltherapeutics.com/phoenix.zhtml?c=92775&p= irol-newsArticle&ID=1332338&highlight=
22. http://investors.celltherapeutics.com/phoenix.zhtml?c=92775&p= irol-newsArticle&ID=1328145&highlight=
23. Borchmann, P., Schnell, R., Morschhauser, F. et al. A phase I study of pixantrone (BBR 2778) in combination with cyclophosphamide, vincristine and prednisolone in patients with relapsed non-Hodgkin's lymphoma. Blood 2003 (ASH Annual Meeting Abstracts), 102(11): Abst 2369.
24. Borchmann, P., Herbrecht, R., Wilhelm, M. et al. Results of a phase II study of pixantrone in combination with cyclophosphamide, vincristine and prednisolone in patients with relapsed aggressive non-Hodgkin's lymphoma. Blood (ASH Annual Meeting Abstracts) 2006, 108(11): Abst 529.
25. Lim, S.T., Hayad, L., Tulpule, A. et al. A phase I/II trial of pixantrone (BBR2778), methyprednisolone, cisplatin and cytosine arabinoside (PSAHP) in relapsed/refractory aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2007, 48(2): 374-80.
26. Rodriguez-Monge, E.J., Cabanillas, F. Long-term follow-up of platinum-based lymphoma salvage regimens. The MD Anderson Cancer Center experience. Hematol Oncol Clin North Am 1997, 11: 937-47.
27. Herbrecht, R., Couban, S., Weissinger, F., Gorbtchevsky, I., Van der Jagt, R.H. CHOP-R (cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab) compared to CPOP-R (cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab) in first-line therapy of diffuse large B-cell lymphoma (DLBCL): An interim analysis. Blood 2007, 110: Abst 3445.
28. Santoro, A., Voglova, J., Gabrail, N. et al. Comparative trail of BBR 2778 (pixantrone) + rituximab vs single agent rituximab in the treatment of relapsed/refractory indolent non-Hodgkin's lymphoma (NHL). J Clin Oncol 2006, 24: 18S (Abst 7578).
29. Fayad, L., Liebmann, J., Modiano, M., Cohen, G., Pro, B., Romaguera, J., Stromatt, S. Results of a phase I/II trial of pixantrone in combination with fludarabine, dexamethasone and rituximab in the treatment of patients with relapsed/refractory indolent non-Hodgkin's lymphoma (NHL). Blood 2006, 108:77 (Abst 2758).
30. Gonsette, R.E. Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis. Expert Opin Pharmacother 2007, 8(8): 1103-16.
31. Mordente, A., Meucci, E., Silvestrini, A., Martona, G.E., Giardina, B. New developments in anthracycline-induced cardiotoxicity. Current Med Chem 2009, 16(13): 1656-72.